Trial Profile
A phase I/II study of Rexmyelocel-T (REX-001) in for the treatment of critical limb ischaemia in patients with diabetes
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 08 Feb 2022
Price :
$35
*
At a glance
- Drugs Rexmyelocel T (Primary)
- Indications Peripheral ischaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Ixaka; Rexgenero
- 22 Jun 2020 Combined results from this and a phase II trial, presented in a Rexgenero media release.
- 04 Aug 2016 New trial record